MP1032 Treatment in Patients With Moderate to Severe COVID-19

NCT04932941 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: MP1032
DRUG: Placebo

Sponsor

MetrioPharm AG

Collaborators

[object Object]